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Abstract
Background: Microarray gene-profiling of invasive breast cancer has identified different subtypes including luminal
A, luminal B, HER2-overexpressing and basal-like groups. Basal-like invasive breast cancer is associated with a worse
prognosis. However, the prognosis of basal-like ductal carcinoma in situ (DCIS) is still unknown. Our aim was to
study the prognosis of basal-like DCIS in a large population-based cohort.
Methods: All 458 women with a primary DCIS diagnosed between 1986 and 2004, in Uppland and Västmanland,
Sweden were included. TMA blocks were constructed. To classify the DCIS tumors, we used immunohistochemical
(IHC) markers (estrogen-, progesterone-, HER2, cytokeratin 5/6 and epidermal growth factor receptor) as a surrogate
for the gene expression profiling. The association with prognosis was examined for basal-like DCIS and other
subtypes using Kaplan-Meier survival analyses and Cox proportional hazards regression models.
Results: IHC data were complete for 392 women. Thirty-two were basal-like (8.2%), 351 were luminal or HER2-
positive (89.5%) and 9 unclassified (2.3%). Seventy-six women had a local recurrence of which 34 were invasive.
Another 3 women had general metastases as first event. Basal-like DCIS showed a higher risk of local recurrence
and invasive recurrence 1.8 (Confidence interval (CI) 95%, 0.8-4.2) and 1.9 (0.7-5.1), respectively. However, the
difference was not statistically significant. Also, no statistically significant increased risk was seen for triple-negative
or high grade DCIS.
Conclusions: Basal-like DCIS showed about a doubled, however not statistically significant risk for local recurrence
and developing invasive cancer compared with the other molecular subtypes. Molecular subtyping was a better
prognostic parameter than histopathological grade.
Background
Increased use of screening mammography, beginning in
the early 1980 s, has resulted in a dramatic increase in
detection of ductal carcinoma in situ (DCIS). DCIS is a
pre-invasive disease with a clinically and molecularly
heterogeneous presentation that poses a major challenge
in both diagnosis and treatment [1-3]. A clinically
accepted classification system predicting prognosis is
still missing.
Recently, the idea of using molecular subtyping to pre-
dict the prognosis of invasive breast cancer has been
widely accepted [4-8]. The introduction of high-
throughput DNA microarray technologies marked an
entirely new era of genome-wide approaches to predict
prognosis and outcome [9,10]. According to similarities
in gene expression characteristics, Perou et al., [11] crea-
tively classified breast cancer into five subtypes: luminal
A, luminal B, basal like, HER2-positive and normal-like.
Molecular subtypes have been shown to have prognostic
and treatment predictive value. Among those, the basal-
like tumors are characterized as expressing genes related
to myoepithelial cells [12]. Follow-up studies have
shown that basal-like cancer is associated with a higher
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risk of disease recurrence, distant metastasis and shorter
survival. The poorer outcome of patients with basal-like
tumors has been shown in different patient populations
[13-17]. However, the prognosis of basal-like DCIS still
unknown.
In this study, our aim was to investigate the prognosis
of basal-like DCIS compared to other subtypes in a
large population-based cohort. To classify the DCIS
tumors, we used immunohistochemical (IHC) markers
that have previously been used as a surrogate marker
for the gene expression profiles [16-21]. Livasy et al.,
have earlier shown that IHC can be used for the identi-
fication of basal like DCIS [18]. We identified the sub-
types of DCIS in tumors from a cohort of 458 women
with tumor material assembled in tissue micro arrays
(TMA) [22]. To our knowledge, this study is the first to
examine the prognosis of DCIS in relation to different
molecular subtypes defined by IHC.
Methods
Patients
We recruited all 458 women who were diagnosed with a
primary DCIS between 1986 and 2004 in Uppland and
Västmanland, Sweden.
TMA construction
H&E sections from all eligible cases were reviewed to
select the area from which the cores for the TMAs would
be taken. Prior to the TMA construction, all primary
DCIS cases were histopathologically re-evaluated by one
pathologist (KJ). Two cores of 1.0 mm in diameter were
mounted into the recipient TMA blocks using a manual
arraying device (MTA-1, Beecher Inc, WI, USA). The
concordance of IHC staining between original whole sec-
tion slides and TMA-slides and between biopsies from
the same lesion in DCIS has earlier been evaluated in a
subset of the cohort [23,24]. In total, ten TMA blocks
were constructed from 458 cancer samples.
IHC and silver-enhanced in situ hybridization (SISH)
We performed IHC for estrogen receptor (ER), proges-
terone receptor (PR), human epidermal growth factor
receptor 2 (HER2), cytokeratin 5/6 (CK5/6) and epider-
mal growth factor receptor (EGFR) on 4 μm paraffin
sections cut from the TMAs. Immunostains for each
marker were performed on a Dako Autostainer (Dako
Corporation). IHC was conducted according to estab-
lished protocols. Appropriate positive and negative con-
trols were included in all staining runs.
HER2 SISH was performed on an automated instru-
ment, Ventana Benchmark (Ventana Medical Systems,
Tucson, AZ), as per the manufacturer’s protocols for
the INFORM HER2 DNA probe and chromosome
17 probes. Testing for the HER2 gene and chromosome
17 was performed on sequential sections. Both probes
are labeled with dinitrophenol. Denaturation occurred
on the instrument with enzyme digestion in protease 3
for 8 minutes. The detection system used a multimer
labeled with goat antirabbit antibody horseradish peroxi-
dase as the linking step. Visualization occurred with the
sequential addition of silver acetate as the source of
ionic silver, hydroquinone, and hydrogen peroxide to
give a black metallic silver precipitate at the probe site.
Counterstaining was performed with hematoxylin II on
the instrument. The time taken for the complete run is
6.5 hours. Both HER2 and chromosome 17 detection
were performed on the same slide run. Gene amplifica-
tion was assessed using the American Society of Clinical
Oncology/College of American Pathologists guideline
and Australian HER2 Advisory Board criteria for single
HER2 probe testing (diploid, 1 to 2.5 copies/nucleus;
polysomy >2.5 to 4 copies/nucleus; equivocal, >4 to 6
copies/nucleus; low-level amplification, >6 to 10 copies/
nucleus; and high-level amplification >10 copies/
nucleus) and for dual HER2/CHR17 probe testing (non-
amplified ratio <1.8; equivocal ratio, 1.8 to 2.2; gene
amplification, >2.2). The status of HER2 protein expres-
sion was assessed relying on SISH. For those cases on
which SISH failed, the expression was based on IHC.
Scoring and classification
Stained TMA slides were scanned (ScanScope® XT,
Aperio, USA) for evaluation of expression of ER, PR,
HER2, CK5/6 and EGFR by ImageScope (Aperio, USA).
Tumor cells that showed nuclear staining for ER or PR
(> 10% of tumor cell nuclei staining) were considered
ER or PR-positive respectively. Using the HerceptTest™-
classification system, tumors were considered HER2
positive if the score was 3+. Cases were considered CK
5/6-positive or EGFR-positive if any cytoplasmic and/or
membranous staining was detected in the tumor cells,
even if focal. These latter IHC criteria are similar to
those previously used for scoring these markers in inva-
sive breast cancers [18,22,25,26]. If only one core
included enough tumor tissue this was used for classifi-
cation but at least 200 cells had to be present. Each
tumor marker was scored by one single observer; ER,
PR and HER2 by WZ, EGFR and CK5/6 by CJ and SISH
by RMA.
For this study, the IHC subtype definitions used were
the refined definitions used in the analysis of invasive
breast cancer: basal-like (ER-, HER2-, EGFR+ and/or
cytokeratin 5/6+) [17]. Cases classified as negative for all
the above markers were defined as unclassified is this
study. Cases with missing data, due to lack of tumor
tissue in the TMAs, were excluded from the further
analyses. In the survival analyses we compared the
basal-like group with all other DCIS together.
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Follow-up and Study End Points
Follow-up started on the day of diagnosis and concluded
on the date the patient was last observed or the date of
death. The database was frozen for the statistical ana-
lyses based on follow-up through 30th April 2008. Com-
plete follow-up was achieved for all 458 patients.
For this study, the two primary end points were local
recurrence and invasive- or general recurrence. Local
recurrence was defined as any ipsilateral recurrence (in
situ or invasive). In addition, we defined “invasive- or
general recurrence” as occurrence of an invasive ipsilat-
eral recurrence, general metastasis or breast cancer-
specific death, whichever occurred first. All women with
an invasive local recurrence were included as cases regard-
ing both endpoints. The endpoint “invasive- or general
recurrence” was constructed to find patients with a biolo-
gically more aggressive disease. Contralateral breast
tumors were considered as new primary breast cancers.
Statistic analyses
Baseline characteristics among patients with different
molecular subtypes were compared by Chi-square for
categorical variables or analysis of variance for continu-
ous variables. Survival and probabilities of local recur-
rence and invasive disease among patients with different
molecular subtypes were first compared by the Kaplan-
Meier method. Cox proportional hazards regression
models were used to calculate hazard ratios (HRs) with
95% confidence intervals (CIs), with adjustment for age
in the univariate analysis and further, histological grade,
type of surgery, tumor size, detection mode and post-
operative radiotherapy in the multivariate analysis.
Kaplan-Meier curves and Cox proportional hazard mod-
els were used to assess the association between molecu-
lar subgroup and progression of breast cancer. Data
were analyzed using the SAS (SAS Institute, Cary, NC)
and R softwares.
This study was approved by the Ethics Committee at
Uppsala University Hospital (Dnr 2005: 118). In this ret-
rospective cohort study we did not have to get an
informed consent from the women according to the
ethical approval, Dnr 170/95 and 99/422.
Results
1. Baseline Characteristics
Baseline characteristics according to the molecular sub-
type of 392 eligible study participants (66 women did
not get enough IHC information) are presented in
Table 1. The median follow-up was 122 months (range
3-130). Among the 392 women, 32 (8.2%) were classi-
fied as basal-like, 351 (89.5%) as luminal or HER2-
positive, and 9 (2.3%) were unclassified. The median age
at diagnose was 58 years (range 30-90 years). All basic
characteristics, including age, tumor size and grade,
were evenly distributed between the basal-like and non
basal-like tumors. No women received antiestrogen or
chemotherapy after primary surgery. Type of surgery,
mastectomy vs. breast conserving surgery (BCS) and
postoperative radiotherapy were decided according to
local tradition. BCS in Sweden means removing a sector
of the breast parenchyma in up to a quadrant of the
breast, aiming for a 10 mm free margin. The breast par-
enchyma is removed from behind the areola margin to
the periphery of the gland. Postoperative radiotherapy
was given to 140 of 298 women undergoing BCS. It was
generally given at 25 occasions, up to 50 Grey. A small
part of these women were included in a Swedish study
randomizing between radiotherapy or not after BCS for
a primary DCIS [27]. Others were given radiotherapy
based on tumor size and histopathological grade. How-
ever, at that time, no criteria for radiotherapy regarding
size or grade were given in the Swedish National
Guidelines.
2. Survival Outcomes
2.1 Local-recurrence
Of the 76 women who had a local recurrence, 42 had an
in situ recurrence and 34 an invasive recurrence. Med-
ian follow-up to local recurrence was 97.5 months
(range 3-255). In both the univariate and multivariate
models, basal-like DCIS showed a higher risk of local
recurrence compared with non basal-like DCIS, hazard
ratio (HR), 1.7 (CI 95%: 0.8-3.8) and 1.8 (0.8-4.2) respec-
tively (Table 2). However, the difference was not statisti-
cally significant. When only looking at women who had
BCS, the risk for basal-like DCIS was equally higher
(Table 2). Kaplan-Meier analyses were also made for all
women and those undergoing BCS separately. The ana-
lyses showed a higher risk for basal-like DCIS compared
to the non basal-like group but it was not statistically
significant. The p-value was 0.08 for all women and 0.26
for women undergoing BCS (Figure 1a).
2.2 Invasive- or general recurrence
Forty-seven women developed invasive disease. Forty-
four had an invasive local recurrence (of which 10 first
had an in situ local recurrence and then an invasive
local recurrence). Three women had general metastases
as the first event. Eight died from breast cancer, but all
of these had had a local recurrence or general metas-
tases before death. Median follow-up to an invasive- or
general recurrence was 111.5 months (range 3-255).
Basal-like DCIS showed a higher risk of invasive- or
general recurrence compared with non basal-like DCIS,
HR, 2.0 (CI 95%: 0.8-5.0) and 1.9 (0.7-5.1) respectively
(Table 2). However, the difference was not statistically
significant. When only looking at women who had BCS,
the risk for basal-like DCIS was also about doubled, but
the risk was not statistically significant higher (Table 2).
Zhou et al. BMC Cancer 2010, 10:653
http://www.biomedcentral.com/1471-2407/10/653
Page 3 of 8
Kaplan-Meier analyses also showed a non-statistically
higher risk for invasive- or general recurrence for the
basal-like DCIS (p = 0.15) as seen in Figure 1b and the
p-value for women undergoing BCS was 0.16.
2.3 Triple-negative group vs. non triple-negative group
We also assessed the prognostic implications of
triple-negative (ER-, PR- and HER2-negative) vs. non
triple-negative DCIS. Of all 458 women, 409 could be
classified. Thirty two were classified as triple-negative
and 377 as not. Triple-negative tumors had a HR of 1.1
(95% CI, 0.4-2.7) and 1.1 (0.4-2.9) for local recurrence
compared with the non triple-negative in the univariate
and multivariate analyses, respectively. The adjusted HR
for an invasive- or general recurrence in the triple-nega-
tive group compared with women in non triple-negative
was 1.4 (0.5-4.0) and 1.6 (0.6-4.8).
Kaplan-Meier analyses showed no statistically signifi-
cantly higher risk for local recurrence or invasive- or
general recurrence for the triple-negative DCIS, neither
in the subset of women undergoing BCS (p = 0.86 and
0.25 respectively) nor including all women (p = 0.67 and
0.44 respectively). (Table 2 and Figure 2a-b).
Of the 392 women with complete IHC data, 32 were
classified as basal-like and 32 as triple-negative. How-
ever, only 24 women were classified as both basal-like
and triple-negative. These subgroups were too small to
do any statistical analyses on but during the follow-up,
the 8 women who were basal-like and non triple-
negative had four invasive- or general recurrences and
the 8 women who were triple-negative and non basal-
like only had one invasive recurrence.
Discussion
We have conducted a population-based study of primary
DCIS to assess the association between an IHC surro-
gate basal-like DCIS genotype and prognosis. Our
results showed that basal-like DCIS had a higher risk of
local recurrence and a higher risk of developing invasive
cancer compared to other DCIS. The risk was almost
doubled but this was not statistically significant.
In our study, we defined basal-like DCIS as those that
were ER-negative, HER2-negative, but positive for either
CK 5/6 or EGFR. Nielsen et al [19], who proposed these
criterions in 2004 for invasive breast cancer, found that
defining basal-like breast cancer in this way resulted in
76% sensitivity and 100% specificity, when the gene
expression signature was used as gold standard. Abd
El-Rehim et al., [28] studied over 1000 cases of invasive
breast cancer with 26 IHC markers and identified 6
clusters of tumors. Five of these clusters roughly corre-
sponded to the 5 subtypes identified earlier; the remain-
ing group consisted of only 4 cases. Livasy et al., [18]
then verified and confirmed the criteria in DCIS tumors.
Today, IHC is increasingly used as a surrogate for mole-
cular gene profiling since it allows classification of
tumors at an affordable costs and in the absence of
fresh tissue speciments [29]. Moreover, these four sub-
groups have distinguishing features closely associated
with subtypes defined by gene expression profiling,
including distinct clinical outcomes [30].
A possible cause of subtype misclassification is the
HER2 status based on IHC scoring. We assessed the sta-
tus of HER2 by SISH and used IHC only in those cases
Table 1 Characteristics of DCIS molecular subgroups, by immunohistochemistry in 392 women with a primary DCIS
Characteristics Basal-like (n = 32, 8.2%) Non basal-like (n = 360, 91.8%) P
Age at entry, mean ± SD (n = 392) 56.7 ± 12.6 57.8 ± 11.5 0.6
Tumor size, number (%) (n = 352) 0.84
≤ 15 m 16 (59.3) 175 (53.9)
> 15 mm 8 (29.6) 104 (32.0)
Multifocal 3 (11.1) 46 (14.2)
Tumor grade*, number (%) (n = 388) 0.11
I 1 (3.1) 29 (8.2)
II 11 (34.4) 171 (48.0)
III 20 (62.5) 156 (43.8)
Detection mode, number (%) (n = 391) 0.3
Screening 22 (68.8) 276 (76.9)
Clinically 10 (31.3) 83 (23.1)
Type of surgery, number (%) (n = 392) 0.61
Breast Conserving Surgery 26 (81.3) 272 (75.6)
Mastectomy 6 (18.8) 88 (24.4)
Postoperative radiotherapy, number (%)(n = 392) 0.72
Yes 10 (31.3) 130 (36.1)
No 22 (68.8) 230 (63.9)
* Tumor grade: DCIS were classified according to the European Organization for Research and Treatment of Cancer (EORTC) system.
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where SISH failed. SISH results are more reliable [31,32]
especially for the borderline cases scored as 2+ by IHC.
By using both methods we should have minimized the
risk of subtype misclassification.
Our results indicated that the molecular subtypes of
DCIS were not related to basic characteristics as histo-
pathological grade and tumor size. However, many
potential prognostic factors may interact with the choice
of adjuvant therapy [29] and we therefore adjusted for
adjuvant treatment and type of surgery in the analyses.
In this study, no women received chemotherapy or anti-
estrogen. One hundred and forty received postoperative
radiotherapy. The percentage of patients who received
postoperative radiotherapy was fairly evenly distributed
among the groups with different subtype of DCIS. The
type of surgery was also evenly distributed.
Basal-like invasive breast cancer is an entity that is lar-
gely characterized by positive expression of basal CKs
and other genes that are characteristic of basal-like cells
and by high proliferative activity. Basal-like invasive
breast cancer is considered to be associated with poor
prognosis [13] and this supposition has been proved in
many studies [4,5,13,17,33,34]. In our study, we found
about a doubled risk for local recurrence and invasive-
or general recurrences for basal-like DCIS. The higher
risk was not statistically significant but, on the other
hand, it was consistent in the univariate, multivariate
and Kaplan-Meier analyses for all patients and for the
subgroup of patients with BCS. Although we have con-
ducted a population-based study with long follow-up,
we were not able to show a statistically significantly
poorer prognosis for the basal-like DCIS. Like in inva-
sive breast cancer, the basal-like subgroup is small and
this makes the statistical power low and a conclusive
study would have to include a much larger number of
patients. Today, we take nuclear grade, size, necrosis
and margins into consideration when designing adjuvant
treatment after BCS of DCIS according to the Swedish
Table 2 Cox regression analyses by molecular subgroup, by immunohistochemistry
All (n = 392) Breast Conserving Surgery (n = 298)
Univariate HR
(95% CI)
Adjusted* HR
(95% CI)
Univariate HR
(95% CI)
Adjusted* HR
(95% CI)
Event: local recurrence (n = 76)
Gene-expression classification
Non basal-like (n = 360) 1 (Reference) 1 1 1
Basal-like (n = 32) 1.7 (0.8-3.8) 1.9 (0.8-4.2) 1.6 (0.7-3.6) 1.8 (0.7-4.2)
Triple-negative classification
Non triple-negative (n = 377) 1 (Reference) 1 1 1
Triple-negative (n = 32) 1.1 (0.4-2.7) 1.1 (0.4-2.9) 1.0 (0.4-2.7) 1.0 (0.3-2.9)
Tumor grade
I (n = 30) 1 (Reference) 1 1 1
II (n = 182) 1.2 (0.4-3.4) 1.4 (0.5-4.0) 1.3 (0.5-3.9) 1.4 (0.5-3.9)
III (n = 176) 1.0 (0.3-2.9) 1.3 (0.5-3.9) 1.4 (0.5-4.0) 1.4 (0.5-4.2)
Postoperation radiotherapy
No (n = 252) 1 (Reference) 1 1 1
Yes (n = 140) 0.9 (0.5-1.5) 0.7 (0.4-1.3) 0.8 (0.4-1.4) 0.7 (0.4-1.4)
Event: invasive- and general recurrence (n = 47)
Gene-expression classification
Non basal-like (n = 360) 1 (Reference) 1 1 1
Basal-like (n = 32) 2.0 (0.8-5.0) 1.9 (0.7-5.1) 2.2 (0.8-5.6) 2.3 (0.8-6.1)
Triple-negative classification
Non triple-negative (n = 377) 1 (Reference) 1 1 1
Triple-negative (n = 32) 1.4 (0.5-4.0) 1.6 (0.6-4.8) 1.7 (0.6-4.9) 2.1 (0.7-6.3)
Tumor grade
I (n = 30) 1 (Reference) 1 1 1
II (n = 182) 1.0 (0.3-3.3) 1.1 (0.3-3.8) 1.1 (0.3-3.8) 1.1 (0.3-3.8)
III (n = 176) 0.7 (0.2-2.4) 1.1 (0.3-3.9) 0.9 (0.2-3.1) 1.0 (0.3-3.9)
Postoperation radiotherapy
No (n = 252) 1 (Reference) 1 1 1
Yes (n = 140) 0.8 (0.4-1.6) 0.7 (0.3-1.5) 0.7 (0.3-1.4) 0.7 (0.3-1.6)
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National Guidelines from the Swedish Breast Cancer
Group [35]. In this study, grade did not relate to prog-
nosis (see Table 2) and molecular subtyping by IHC
might indeed be more useful.
We also investigated the prognosis of triple-negative
DCIS. In invasive cancer, triple-negative tumors have
been shown to have a worse prognosis [36-38].
We observed a slightly elevated risk for developing inva-
sive disease, but this was not statistically significant. In
some studies, triple-negative and basal-like DCIS cases
have been considered to have a fairly similar prognosis.
In our study, there was a considerable miss-match
between these cases as already described in invasive
breast cancer by others [21,39,40].
Conclusions
In conclusion, basal-like DCIS showed about a doubled,
however not statistically significant risk for local recur-
rence and developing invasive cancer compared with the
other molecular subtypes. In this study, molecular sub-
typing was a better prognostic parameter than histo-
pathological grade.
(a)                                                       (b)  
Figure 1 Kaplan-Meier analyses of local recurrence and invasive- and general recurrence by DCIS molecular subgroup by
immunohistochemistry. (a) Local recurrence (in situ or invasive) in women with a primary DCIS, undergoing breast-conserving surgery (BCS),
by molecular subtype. (b) Invasive- or general recurrence in all women with a primary DCIS by molecular subtype.
(a) (b)
Figure 2 Kaplan-Meier analysis of local recurrence and invasive- and general recurrence by triple-negative and non triple-negative
DCIS. (a) Local recurrence (BCS), triple negative DCIS vs. non-triple negative DCIS. (b) Invasive- or general recurrence in all women, triple
negative DCIS vs. non-triple negative DCIS.
Zhou et al. BMC Cancer 2010, 10:653
http://www.biomedcentral.com/1471-2407/10/653
Page 6 of 8
List of abbreviations
DCIS: ductal carcinoma in situ; IHC: immunohistochemistry; CI: Confidence
interval; HR: hazard ratio; TMA: tissue microarrays; ER: oestrogen receptor; PR:
progesterone receptor; HER2: human epidermal growth factor receptor 2;
CK5/6: cytokeratin 5/6; EGFR: epidermal growth factor receptor.
Acknowledgements
This study was supported by the Swedish Cancer Society (4920-B06-03PCD
to FW). We thank Hans Garmo for his initial work in the data analysis.
Author details
1Department of Surgical Science, Uppsala University, Uppsala, SE-75105,
Sweden. 2Department of Laboratory Medicine, Lund University, Lund,
Sweden. 3Department of Genetics and Pathology, Uppsala University,
Uppsala, Sweden. 4Department of Oncology, Helsinki University Central
Hospital, Finland. 5School of Medicine, Division of Cancer Studies, King’s
College, London, UK.
Authors’ contributions
WZ was responsible for data analyses, manuscript preparation and editing.
KJ performed IHC and SISH stainings from the TMAs, and helped to provide
expertise in breast cancer pathology. WZ, JC and RMA were involved in
pathology review, scoring of stains and contributed substantially to
manuscript editing. CB helped with the interpretation of the results and
with drafting the manuscript. OA helped to provide expertise in data
analyses. FW designed the overall study, compiled and curated the datasets,
coordinated the study and helped to draft and finalize the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 17 July 2010 Accepted: 30 November 2010
Published: 30 November 2010
References
1. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J,
Klein J, Fridman E, Skarda J, Srovnal J, et al: Novel markers for
differentiation of lobular and ductal invasive breast carcinomas by laser
microdissection and microarray analysis. BMC cancer 2007, 7:55.
2. Tsikitis VL, Chung MA: Biology of ductal carcinoma in situ classification
based on biologic potential. American journal of clinical oncology 2006,
29(3):305-310.
3. Namba R, Maglione JE, Davis RR, Baron CA, Liu S, Carmack CE, Young LJ,
Borowsky AD, Cardiff RD, Gregg JP: Heterogeneity of mammary lesions
represent molecular differences. BMC cancer 2006, 6:275.
4. Zhao J, Liu H, Wang M, Gu L, Guo X, Gu F, Fu L: Characteristics and
prognosis for molecular breast cancer subtypes in Chinese women. J
Surg Oncol 2009, 100(2):89-94.
5. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A: Breast cancer
classification according to immunohistochemical markers:
clinicopathologic features and short-term survival analysis in a
population-based study from the South of Switzerland. Ann Oncol 2009,
20(4):628-635.
6. Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P,
Narod SA, Hanna WM: Patterns of recurrence in the basal and non-basal
subtypes of triple-negative breast cancers. Breast Cancer Res Treat 2009.
7. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW,
Flagg EW, O’Regan RM, Gabram SG, Eley JW: Race and triple negative
threats to breast cancer survival: a population-based study in Atlanta,
GA. Breast Cancer Res Treat 2009, 113(2):357-370.
8. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B,
Desmedt C, Ignatiadis M, Sengstag T, Schutz F, et al: Meta-analysis of gene
expression profiles in breast cancer: toward a unified understanding of
breast cancer subtyping and prognosis signatures. Breast Cancer Res
2008, 10(4):R65.
9. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of
gene expression patterns with a complementary DNA microarray.
Science 1995, 270(5235):467-470.
10. Pease AC, Solas D, Sullivan EJ, Cronin MT, Holmes CP, Fodor SP: Light-
generated oligonucleotide arrays for rapid DNA sequence analysis.
Proceedings of the National Academy of Sciences of the United States of
America 1994, 91(11):5022-5026.
11. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast
tumours. Nature 2000, 406(6797):747-752.
12. Sorlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Borresen-
Dale AL: Distinct molecular mechanisms underlying clinically relevant
subtypes of breast cancer: gene expression analyses across three
different platforms. BMC Genomics 2006, 7:127.
13. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T,
Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of
breast carcinomas distinguish tumor subclasses with clinical
implications. Proceedings of the National Academy of Sciences of the United
States of America 2001, 98(19):10869-10874.
14. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S,
Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast
tumor subtypes in independent gene expression data sets. Proceedings
of the National Academy of Sciences of the United States of America 2003,
100(14):8418-8423.
15. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P,
Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based
on gene expression profiles from a population-based study. Proceedings
of the National Academy of Sciences of the United States of America 2003,
100(18):10393-10398.
16. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R:
Prognostic relevance of basal cytokeratin expression in operable breast
cancer. Oncology 2005, 69(6):478-485.
17. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G,
Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and
survival in the Carolina Breast Cancer Study. JAMA 2006,
295(21):2492-2502.
18. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK,
Nyante S, Millikan RC: Identification of a basal-like subtype of breast
ductal carcinoma in situ. Hum Pathol 2007, 38(2):197-204.
19. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-
Boussard T, Livasy C, Cowan D, Dressler L, et al: Immunohistochemical and
clinical characterization of the basal-like subtype of invasive breast
carcinoma. Clin Cancer Res 2004, 10(16):5367-5374.
20. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR,
Smith IE: Basal-like breast carcinomas: clinical outcome and response to
chemotherapy. J Clin Pathol 2006, 59(7):729-735.
21. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM,
Nielsen TO: Basal-like breast cancer defined by five biomarkers has
superior prognostic value than triple-negative phenotype. Clin Cancer Res
2008, 14(5):1368-1376.
22. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT,
Perou CM: Phenotypic evaluation of the basal-like subtype of invasive
breast carcinoma. Mod Pathol 2006, 19(2):264-271.
23. Warnberg F, Amini RM, Goldman M, Jirstrom K: Quality aspects of the
tissue microarray technique in a population-based cohort with ductal
carcinoma in situ of the breast. Histopathology 2008, 53(6):642-649.
24. Jirstrom K, Ringberg A, Ferno M, Anagnostaki L, Landberg G: Tissue
microarray analyses of G1/S-regulatory proteins in ductal carcinoma in
situ of the breast indicate that low cyclin D1 is associated with local
recurrence. Br J Cancer 2003, 89(10):1920-1926.
25. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO,
Lundin M, Krogh M, Kataja P, Borg A, Ferno M, et al: Basal-like phenotype
is not associated with patient survival in estrogen-receptor-negative
breast cancers. Breast Cancer Res 2007, 9(1):R16.
26. Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM,
Makambi KH, Adams-Campbell L, Frederick WA: Molecular breast cancer
subtypes in premenopausal African-American women, tumor biologic
factors and clinical outcome. Ann Surg Oncol 2007, 14(10):2994-3003.
27. Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H,
Anderson H, Garmo H, Holmberg L, Wallgren A: SweDCIS: Radiotherapy
after sector resection for ductal carcinoma in situ of the breast. Results
of a randomised trial in a population offered mammography screening.
Acta Oncol 2006, 45(5):536-543.
Zhou et al. BMC Cancer 2010, 10:653
http://www.biomedcentral.com/1471-2407/10/653
Page 7 of 8
28. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF,
Macmillan D, Blamey RW, Ellis IO: High-throughput protein expression
analysis using tissue microarray technology of a large well-characterised
series identifies biologically distinct classes of breast cancer confirming
recent cDNA expression analyses. Int J Cancer 2005, 116(3):340-350.
29. Tang P, Wang J, Bourne P: Molecular classifications of breast carcinoma
with similar terminology and different definitions: are they the same?
Hum Pathol 2008, 39(4):506-513.
30. Tang P, Skinner KA, Hicks DG: Molecular classification of breast
carcinomas by immunohistochemical analysis: are we ready? Diagn Mol
Pathol 2009, 18(3):125-132.
31. Francis GD, Jones MA, Beadle GF, Stein SR: Bright-field in situ
hybridization for HER2 gene amplification in breast cancer using tissue
microarrays: correlation between chromogenic (CISH) and automated
silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol
2009, 18(2):88-95.
32. Shousha S, Peston D, Amo-Takyi B, Morgan M, Jasani B: Evaluation of
automated silver-enhanced in situ hybridization (SISH) for detection of
HER2 gene amplification in breast carcinoma excision and core biopsy
specimens. Histopathology 2009, 54(2):248-253.
33. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD,
DeWitty RL, Frederick WA: Treatment and survival outcome for molecular
breast cancer subtypes in black women. Ann Surg 2008, 247(3):463-469.
34. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B,
Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A,
et al: Differences in risk factors for breast cancer molecular subtypes in a
population-based study. Cancer Epidemiol Biomarkers Prev 2007,
16(3):439-443.
35. [http://www.swebcg.se/index.asp?P=NatRikt].
36. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast Cancer Subtypes
Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic
Features and Survival. Clin Med Res 2009, 7(1-2):4-13.
37. Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-
Bertram S, Traut A, Bois AD: Triple-negative and HER2-overexpressing
breast cancers exhibit an elevated risk and an earlier occurrence of
cerebral metastases. Eur J Cancer 2009.
38. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW: The
epidemiology of triple-negative breast cancer, including race. Cancer
Causes Control 2009.
39. Thike AA, Iqbal J, Cheok PY, Chong AP, Tse GM, Tan B, Tan P, Wong NS,
Tan PH: Triple Negative Breast Cancer: Outcome Correlation With
Immunohistochemical Detection of Basal Markers. Am J Surg Pathol .
40. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG,
El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA et al: Triple-negative
breast cancer: distinguishing between basal and nonbasal subtypes. Clin
Cancer Res 2009, 15(7):2302-2310.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/653/prepub
doi:10.1186/1471-2407-10-653
Cite this article as: Zhou et al.: Long-term survival of women with
basal-like ductal carcinoma in situ of the breast: a population-based
cohort study. BMC Cancer 2010 10:653.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhou et al. BMC Cancer 2010, 10:653
http://www.biomedcentral.com/1471-2407/10/653
Page 8 of 8
